Calciplus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calciplus

Calciplus is the trade name for a specific prescription medicinal preparation whose active component is Calcitonin Salmon (Salcatonin). It is fundamentally classified as a polypeptide hormone used to regulate bone metabolism and calcium levels in the body, primarily designated as a hypocalcemic agent and a bone resorption inhibitor. It is supplied in two forms: a nasal solution for intranasal delivery and a solution for injection for parenteral administration.


Quick Facts

Property Description
Active ingredient Calcitonin Salmon (Salcatonin)
Form Nasal Solution (Spray) or Solution for Injection
Pharmacological class Calcitonin, Hypocalcemic Agent
General purpose Inhibition of bone breakdown; Calcium level regulation
Origin Synthetic Peptide (Biotechnological)

What Type of Medicine is Calciplus?

Calciplus is a prescription-only medication whose active ingredient, Calcitonin Salmon, places it within the pharmacological class of Calcitonins, functioning as a hypocalcemic agent and a bone resorption inhibitor. This classification identifies it as a specialized drug designed to regulate calcium metabolism and slow the continuous breakdown of bone tissue in the body. This hormonal class of agents operates distinctly from other common bone medications, such as bisphosphonates, by directly binding to and inhibiting the activity of osteoclasts—the cells responsible for bone reabsorption.


Calcitonin Salmon: Composition and Origin

The essential substance in Calciplus is Calcitonin Salmon (INN: Salcatonin), a synthetic polypeptide hormone consisting of 32 amino acids. This compound is manufactured to replicate the structure of the naturally occurring hormone found in Salmon species. This synthetic salmon version possesses enhanced potency and a longer duration of action compared to its human counterpart. This means the drug is structured to provide a more lasting regulatory effect on the body's bone and calcium processes. As a single-active ingredient product, its composition focuses entirely on the targeted effects of the peptide, delivered in an aqueous solution base suitable for its specialized routes of administration.


General Purpose: What Does Calciplus Do?

The general purpose of Calciplus is to preserve bone mass and support the structural integrity of the skeleton by modulating specific biological processes. It achieves this by inhibiting the action of bone-destroying cells, thereby significantly reducing the rate of bone mineral loss. Furthermore, the medication has a distinct physiological action: it acts to rapidly regulate and decrease abnormally elevated calcium levels in the blood. For instance, its action is recognized for counteracting rapid bone loss and stabilizing the associated metabolic condition. This dual hormonal action supports the overall benefit of maintaining a healthy balance between bone formation and resorption.

Regulatory References

  1. Calcitonin - StatPearls - NCBI

What side effects are possible with Calciplus?

Possible Side Effects and Safety Information

The safety profile for Calciplus (Calcitonin Salmon) is documented in official regulatory labeling, categorizing adverse reactions by frequency and affected organ system. Reactions are often specific to the route of administration, whether as a nasal solution or a solution for injection.


Adverse Reaction Classifications

Classification Examples of Documented Effects
Very Common (ge 1/10) Nausea, Flushing (facial/upper body), Rhinitis, Injection site reactions.
Common (ge 1/100 to <1/10) Headache, Dizziness, Back pain, Arthralgia, Diarrhea, Epistaxis (nosebleed).

Serious Safety Considerations

Official documents note the risk of Serious Hypersensitivity Reactions, including anaphylaxis and life-threatening anaphylactic shock. The possibility of Severe Hypocalcemia (very low calcium levels) leading to tetany or seizures is also documented. Furthermore, an increased risk of overall malignancies has been noted in meta-analyses of long-term use, a concern associated with prolonged exposure.

Time- and Population-Related Notes

Some effects, such as nausea, are typically more pronounced upon initiation of therapy and may lessen with continued use. The malignancy concern is tied to long-term exposure. Safety constraints include the need for pre-existing hypocalcemia to be corrected before treatment begins. Regulatory documents also note that older adults using the nasal spray may experience a higher incidence of local nasal side effects. The medication is not recommended for use during pregnancy or lactation.

Overdose and Emergency Response

Calciplus Overdose and when to seek help

The official regulatory profile for Calciplus (Calcitonin Salmon) overdose is defined by its primary pharmacological function as a hypocalcemic agent. An excessive dose is documented as leading to an exaggerated hypocalcemic effect, which is an abnormal and potentially profound reduction in blood calcium levels. Clinical documentation reports that overdose may present with gastrointestinal disturbances, including nausea and vomiting. More serious manifestations, often associated with dangerously low calcium, are listed as tetany and potential for Severe Symptomatic Hypocalcemia, which is a life-threatening outcome.


Emergency Response and Management

Immediate medical attention is the required course of action for any suspected overdose, as mandated by regulatory guidelines. Individuals must contact emergency services without delay due to the potential for severe outcomes stemming from the hypocalcemia. The official regulatory text states explicitly that no specific antidote is known for Calcitonin Salmon. Consequently, the mandated management protocol is focused on supportive measures. This officially described treatment includes the necessary administration of intravenous calcium to rapidly correct the physiological imbalance, alongside mandatory close clinical observation and continuous monitoring of serum calcium levels until the patient's condition is stable. This protocol is defined by the necessity of reversing the severe physiological effects documented in the overdose profile.

Therapeutic Uses of Calciplus

What Calciplus Treats: Main Uses and Benefits

Calciplus is generally considered a specialized prescription medication that plays a role in managing several conditions related to bone metabolism and calcium regulation. It is considered relevant for easing symptoms in areas where additional symptomatic support is needed across three primary indications: Postmenopausal Osteoporosis, Paget’s disease of bone, and Hypercalcemia.

Therapeutic Focus and Patient Benefit

This medication is commonly used across conditions presenting with acute systemic imbalance or chronic disorders marked by excessive bone breakdown. In urgent settings, such as with significantly elevated calcium levels, it contributes to the management of elevated serum calcium, which is relevant for supporting the patient's stability. For chronic conditions, it supports skeletal integrity and supports in addressing the risk of new vertebral fractures. It is also applied in addressing symptoms related to acute physical discomfort, such as severe bone pain linked to fractures.

“This approach is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability during difficult episodes.”

Quick Fact

Property Description
Quick Fact: Relief for Acute Discomfort Calciplus is commonly used to help ease the intensity of severe bone pain associated with acute vertebral compression fractures.

Eligibility and Restrictions for Use

Who can and cannot use Calciplus?

Eligibility for Calciplus (Calcitonin Salmon) is strictly defined by regulatory criteria, often reserving its use for patients who cannot take or tolerate alternative treatments.

Eligibility Status Population Rule (Official Labeling)
Contraindicated Patients with known hypersensitivity to Calcitonin Salmon or any excipients. Patients with existing hypocalcemia (low calcium levels).
Not Recommended Pediatric patients (safety/effectiveness not established). Breastfeeding women. Females of reproductive potential (for the nasal spray form).

Condition-Based Restrictions: Hypocalcemia and mineral metabolism disorders, such as Vitamin D deficiency, must be corrected before starting therapy. Treatment is limited in duration and must be periodically re-evaluated due to a reported possible increased risk of malignancy with long-term use. Pregnancy use is generally not studied and should only occur if the treatment is deemed absolutely essential.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation notes that formal studies designed to evaluate drug interactions with Calciplus (Calcitonin Salmon) have not been completed for many co-administered medicinal products. The officially documented interaction profile is focused on specific pharmacokinetic changes and disease-specific observations.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Type of Interaction Interacting Substance Official Interaction Pattern
Pharmacokinetic (Increased Clearance) Lithium Co-administration leads to a reduction in plasma lithium concentrations due to increased urinary clearance of Lithium, as stated in prescribing information.
Pharmacodynamic (Response Modification) Diphosphonates Prior use appears to reduce the anti-resorptive response to Calciplus, an observation specific to patients with Paget’s disease of bone.

Interaction-Related Procedural Constraints

The official label states that co-administration with other agents is not restricted by mandatory time separation rules. However, a significant restriction is placed on the patient’s existing mineral status. Disorders affecting mineral metabolism, such as hypocalcemia or Vitamin D deficiency, must be corrected prior to the initiation of Calciplus therapy. No interactions with food, alcohol, or common herbal supplements are explicitly documented in regulatory materials.

This interaction structure reflects the specific patterns verified and included in authoritative government-issued prescribing information.

Mechanism of Action

The mechanism of Calciplus centers on its action as a specific agonist at the Calcitonin Receptor (CTR). This receptor is primarily expressed on osteoclasts, the cells responsible for bone resorption. Activation of the CTR triggers an immediate intracellular cascade that rapidly disrupts the osteoclast's actin cytoskeleton, forcing the cell to retract and lose its bone-dissolving structure. This molecular event results in the rapid cessation of bone resorption, arresting the release of calcium and phosphate from bone tissue into the bloodstream. Systemically, the mechanism also involves influencing the renal system. CTR activation in the kidney tubules causes a decrease in the reabsorption of calcium and other ions, leading to increased excretion. This concerted action on bone and kidney clearance produces a rapid physiological reduction in serum calcium concentration. Additionally, the drug activates CTR in specific regions of the central nervous system (CNS) involved in pain processing, influencing signal transmission in descending pain pathways as part of its pharmacological profile.

Dosage and Administration Information

How to Use Calciplus

Calciplus (Calcitonin Salmon) is administered using specific, indication-based protocols. Usage is determined by the required route of administration, which includes intranasal delivery via a metered-dose spray and parenteral delivery via subcutaneous (SC), intramuscular (IM), or intravenous (IV) injection.


Administration Regimens

The dosage and frequency are dependent on the condition being addressed:

  • Postmenopausal Osteoporosis: The standard regimen is 200 International Units (IU) administered once daily as a single spray, with the nostril used alternated daily.
  • Paget’s Disease of Bone: Initial treatment is typically 100 IU via SC or IM injection once daily. A maintenance dose of 50 IU daily or 50 IU to 100 IU three times a week may be used following clinical response.
  • Acute Hypercalcemia: The starting dose is usually 4 IU/kg body weight via SC or IM injection every 12 hours, which may be increased to a maximum of 8 IU/kg every 6 hours for severe cases.

Procedural and Time-Based Use

For non-acute bone conditions, such as Osteoporosis, the regimen includes mandatory co-administration: patients must receive adequate supplemental calcium and Vitamin D intake. When administered via SC injection, patients are instructed to rotate the injection site to minimize local reactions. The injection may be administered at bedtime as a common practice to potentially reduce associated nausea.

Treatment duration is subject to constraint: use for acute hypercalcemia is generally short-term (e.g., 48 to 72 hours). For chronic conditions, long-term use requires periodic re-evaluation and the therapy is typically discontinued once satisfactory clinical and biochemical responses are achieved.

Recent Clinical Evidence

Research evidence / Overview of studies for Calciplus

Evidence for Use in Postmenopausal Osteoporosis

Research for this indication includes large Randomized Controlled Trials (RCTs) and Meta-analyses evaluating vertebral fracture incidence and Bone Mineral Density (BMD) in postmenopausal women. Studies reported patterns of higher measured BMD in the spine. However, the overall evidence landscape is characterized by low certainty. Findings were inconsistent regarding the change in fracture incidence, and the research does not consistently document a pattern for non-vertebral fractures.


Evidence for Use in Paget’s Disease of Bone

The evidence is drawn from smaller Clinical Trials that examined biochemical markers and patient-reported bone pain for symptomatic Paget's disease. Studies monitored changes in these markers, reporting patterns observed in the studies. The level of certainty is moderate. A key limitation is the potential for patients to develop neutralizing antibodies, which is observed to be related to a diminished initial response over the long term.


Evidence for Use in Acute, Elevated Calcium Levels (Hypercalcemia)

Research utilized acute Interventional Studies to monitor the rate of change in serum corrected calcium levels. The findings indicate a pattern of rapid-onset change in calcium levels, considered to be of moderate to high certainty. The research describes limitations that restrict its use to short-term stabilization due to tachyphylaxis (diminishing response with repeated use). It is typically studied alongside other slower-acting therapies.


Key Limitations and Areas of Research Uncertainty

Long-term data consistency is a primary area of uncertainty, particularly the inconsistent fracture findings for osteoporosis and the diminishing response documented for Paget’s disease. Data for specialized populations, such as pediatric or complex comorbidity groups, remain insufficient, and evidence quality varies across studies due to smaller sample sizes.

Key Studies & References Calcitonin Salmon Injection USP Prescribing Information (FDA-approved label)

Frequently Asked Questions (FAQ)

Common questions about Calciplus (FAQ)

Q: What is the main difference between Calciplus and regular calcium supplements?

Calciplus (Calcitonin Salmon) is officially classified as a synthetic polypeptide hormone that works by stopping bone breakdown, a process known as inhibiting osteoclasts. This is functionally different from regular calcium supplements, which are classified as a mineral nutrient used to provide the body with the building blocks for bone. Both are sometimes used as part of a treatment plan, but they serve different biological functions.

Q: What are the most common reasons people stop using Calciplus?

Official documentation indicates that reasons for discontinuing Calciplus often relate to managing side effects like nausea and flushing, which have been documented as sometimes severe. For chronic use, therapy is subject to re-evaluation due to the documented potential for a diminished response over time and a reported increased risk of malignancy (cancer).

Q: What should I do if I am already taking a lot of vitamins and want to start Calciplus?

The official product information specifies that Vitamin D deficiency and other mineral disorders must be corrected before starting Calciplus. Adequate intake of both calcium and Vitamin D is a required component of the treatment regimen to manage your bone health. Regulatory documents also note that the drug may affect the levels of other minerals, such as increasing magnesium, by decreasing how much is cleared by the kidney.

Q: What is the difference between how Calciplus works compared to Vitamin D supplements alone?

Calciplus (Calcitonin Salmon) is described as acting immediately to stop the action of bone-destroying cells (osteoclasts). In contrast, Vitamin D primarily helps the body absorb calcium from food and regulates calcium levels. Official guidance states that patients often receive both Calciplus and supplemental Vitamin D to ensure a complete approach to bone health.

Q: Can Calciplus be crushed or split if someone has trouble swallowing pills?

Regulatory documentation clarifies that Calciplus is not manufactured as a solid oral tablet or pill. It is only supplied as a solution for injection or a nasal spray. Therefore, the medication is not designed to be crushed or split.

Q: What is the experience of people who have used Calciplus for over a year?

Official safety reports summarize the experience of long-term use, indicating that therapy lasting over one year has been linked to a potential, small increase in the overall risk of malignancy (cancer). Additionally, a diminishing response has been observed in some patients with chronic conditions, meaning its effect may lessen over time.

Q: Can men and women use Calciplus for the same conditions?

The official label indicates that Calciplus is specifically indicated for postmenopausal osteoporosis in women. However, it is also indicated for conditions like Paget's disease and acute hypercalcemia, which are conditions that can affect both men and women.

Q: What are the common benefits reported by patients using Calciplus?

Official clinical studies have measured benefits in terms of objective outcomes like increased bone mineral density (BMD) in the spine and a reduction in bone pain for Paget's disease. For acute conditions, the benefit is the rapid stabilization of high calcium levels. These findings describe the drug’s intended action in modulating bone and calcium metabolism.

Q: Why do some people need Calciplus and not just a change in diet?

Regulatory documents reserve Calciplus for specific conditions where a targeted hormonal action is necessary. It is designed to directly and rapidly inhibit bone breakdown and lower elevated calcium levels. The severity of the condition often requires the specific hormonal action of the medication in addition to nutritional support.

Q: What happens if I forget to use Calciplus sometimes?

According to official patient instructions for a daily dose, if you remember the missed dose the same day, you may use it as soon as you remember. If it is already the next day, regulatory guidance advises skipping the missed dose and simply continuing with the regular dosing schedule. Official instructions strictly state not to take a double dose.

Q: Does Calciplus affect sleep or cause fatigue?

Regulatory safety reports list unusual tiredness or weakness (sometimes called fatigue) as a less common, documented side effect. Sleep disturbances or insomnia are not explicitly listed in the official safety classification tables for this medication.

Q: Does Calciplus interact with common over-the-counter pain relievers?

Official prescribing information does not list specific interactions with common over-the-counter (OTC) pain relievers. However, certain studies have noted that the drug may have an effect that potentiates the pain-relieving effects of some central nervous system medications.

Q: Is it possible for Calciplus to interfere with blood pressure medicines?

Official safety documents list hypertension (high blood pressure) as a documented cardiovascular side effect of Calciplus. The presence of this reported side effect suggests that patients taking blood pressure medication may require monitoring for any changes during treatment.

Q: Is there a generic version of Calciplus available?

Regulatory records indicate that a generic version of the Calcitonin Salmon injection is approved and available. However, a generic formulation of the Calcitonin Salmon nasal spray is not currently available in the market.

Q: Can someone who is lactose intolerant use Calciplus?

The official labeling for the liquid forms (injection and nasal spray solutions) generally lists a simple aqueous base and stabilizers as inactive ingredients. Regulatory listings indicate that lactose is not typically an excipient (filler) used in these liquid formulations.

Q: What does the patient leaflet mean by a 'contraindication' for Calciplus?

According to official patient safety information, a contraindication is a specific condition or circumstance where the medication should not be used because the risk of harm is significantly greater than any potential benefit. Examples include a known severe allergy to the drug or an existing case of hypocalcemia (very low calcium levels).

Q: Does Calciplus cause weight gain or loss?

Official product labels list unusual weight gain or loss as a documented adverse reaction. This change in weight is generally considered an uncommon side effect.

Q: Is Calciplus considered a 'high-risk' medication?

Official documents define the safety profile by listing serious concerns, including the risks of anaphylaxis (a life-threatening allergic reaction), severe hypocalcemia (low calcium levels), and a potential increased risk of malignancy (cancer) with long-term use.

Q: Are there any restrictions on driving or operating machinery while using Calciplus?

The official adverse reaction tables list side effects such as dizziness and, less commonly, visual or hearing impairment. These documented effects may temporarily affect an individual's ability to safely drive or operate heavy machinery.

Q: What is the shelf life of Calciplus after the package is opened?

Official storage instructions for the nasal spray specify that the unopened spray must be refrigerated. Once the spray is opened and primed, it is recommended to store it at room temperature and regulatory guidance requires that it be discarded after 35 days, regardless of how much medicine remains inside the bottle.

Q: Can Calciplus cause dry mouth or changes in taste?

Official regulatory safety documentation records changes in sense of taste (sometimes described as a salty taste) and dry mouth as documented, though less common, side effects of the medication.

Q: Is Calciplus safe for patients with a history of heart issues?

Regulatory labels report cardiovascular side effects for Calciplus, including hypertension (high blood pressure) and chest pain. Patients who have pre-existing heart conditions are advised to discuss these documented risks with a healthcare professional.

Q: How long does Calciplus stay in the body after the last use?

Official pharmacology information indicates that the active component, Calcitonin Salmon, has a very short elimination half-life of approximately 43 minutes. The drug is quickly broken down by the kidney and cleared from the body through the urine.

Q: What happens if I mistakenly use too much Calciplus once?

Official drug information advises that if you suspect you have used too much Calciplus, official guidance advises immediately contacting the Poison Control Helpline or seeking emergency medical help. Severe nausea and vomiting are listed as potential symptoms of using too much.

How should Calciplus be stored and disposed of?

How to Store and Dispose of Calciplus?

Strict adherence to official storage and disposal requirements ensures the medicine's quality and safety. Calciplus must be stored at a defined temperature, typically below 25°C (or as specified on the package label). It is mandatory to keep this medicine out of the sight and reach of children.

Storage Requirements

Condition Requirement
Temperature Store below 25 C unless otherwise indicated.
Protection Keep in the original container to protect from light and moisture.
Handling Do not use beyond the expiration date printed on the carton.

Disposal Instructions

Unused or expired Calciplus must be disposed of in accordance with local regulatory requirements. Do not dispose of this medicine via household waste or wastewater unless specifically instructed to do so by local health officials.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calciplus found in:

A-Z Index: